Republicans in swing states say they see scant signs of groups door-knocking for Trump
21 wounded after Russia strikes apartment buildings in Ukrainian city of Kharkiv
German chancellor's Social Democrats seek to hold off far right in Brandenburg state election
Pope condemns killing of Honduran environmental activist
Israeli strike kills seven in Gaza school compound, Palestinian medics say
Japan PM hopeful Ishiba sees 'room' for corporate tax hike, Kyodo reports
Southwest Airlines warns staff of 'tough decisions' ahead, Bloomberg reports
GM to lay off about 1,700 workers at Kansas plant
Sanders connects with Wester on Hail Mary in regulation, Colorado beats Baylor 38-31 in overtime
Hong Kong’s first transgender singer-songwriter seeks voice through music
Biles and Chiles to headline "Gold Over America Tour"
(Reuters) - Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".
The contract drug manufacturer was expected to file the report on Aug. 29.
The company is awaiting the closing of the $16.5 billion takeover deal signed in February by Novo Holdings, the investment firm that has a controlling interest in Danish drugmaker Novo Nordisk.
Catalent expects the deal to close towards the end of the year.
Catalent is a contractor that does fill-finish work, which involves the filling and packaging of syringes and injection pens in sterile conditions, including Novo Nordisk's blockbuster drug Wegovy.
The U.S. Federal Trade Commission in May sought more information on the deal, after Novo Holdings prefiled an application seeking the antitrust agency's nod.
The company beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
(Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel)
